THIERRY PAPER

About THIERRY PAPER

Thierry Paper is a leading executive figure in the governance of BIOSYNEX, a French in vitro diagnostics group. He helped create the company in 2005 and initially served as its General and Operational Director. In June 2015, he was appointed Deputy Chief Executive Officer of the BIOSYNEX group, a role that reflects his continued involvement in the company’s strategic, operational, and commercial development. His background is deeply rooted in pharmacy, medical biology, and diagnostics. Thierry Paper studied pharmacy at Université Paris V, completing both the first and second cycles of pharmaceutical studies. He also earned a postgraduate diploma in medical biology from the same university and later completed an MBA at the École Nationale des Ponts et Chaussées. After working as a pharmacy intern until May 1990, he joined Orgenics, an Israeli diagnostics company, where he worked as a project manager and then as a marketing manager. He later led development at Matara from 1993 to 1997, and then served as deputy director of the J-P Accary medical analysis laboratory from 1997 to 2005. In parallel, he has managed AXODEV, a business development services firm focused on the in vitro diagnostics industry, since 1997. At BIOSYNEX, Thierry Paper has played a central role in building a recognized player in rapid diagnostic testing and point-of-care solutions. The company highlights its expertise in designing, manufacturing, and marketing innovative diagnostic products, supported by international growth and scientific partnerships. His profile combines technical credibility in medical biology, commercial experience in diagnostics, and entrepreneurial leadership gained across laboratory and healthcare businesses. That combination has been instrumental in BIOSYNEX’s development and scale-up. More broadly, Thierry Paper represents the profile of a French healthtech executive who bridges scientific expertise, operational execution, and corporate growth strategy. His career illustrates a consistent progression from pharmaceutical training to diagnostics industry management and, ultimately, to the co-creation and leadership of a listed healthcare company.